Last reviewed · How we verify
MK-4280
MK-4280 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells to the tumor microenvironment.
MK-4280 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells to the tumor microenvironment. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | MK-4280 |
|---|---|
| Also known as | Favezelimab |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | CCR4 antagonist |
| Target | CCR4 (C-C chemokine receptor type 4) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CCR4 is highly expressed on regulatory T cells (Tregs) and certain activated T cell populations. By blocking CCR4, MK-4280 depletes Tregs from tumors, reducing immunosuppression and allowing enhanced anti-tumor immune responses. This mechanism aims to enhance the efficacy of checkpoint inhibitors and other immunotherapies.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Lymphopenia
- Infection
- Fatigue
- Diarrhea
Key clinical trials
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (PHASE2)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (PHASE3)
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (PHASE1, PHASE2)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (PHASE2)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (PHASE3)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (PHASE3)
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (PHASE2)
- Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-4280 CI brief — competitive landscape report
- MK-4280 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI